Results 201 to 210 of about 27,421 (247)

Osteoprotegerin

Ortopedia, traumatologia, rehabilitacja, 2012
In 1997, a glycoprotein was isolated that blocked osteoclast differentiation from precursor cells. This protein prevented osteoporosis when administered to ovariectomized rats, and led to osteopetrosis when overexpressed. This newly discovered protein was named osteoprotegerin (OPG).
Marleen A. Baak, Bernard Gutin, Kim A. Krawczewski Carhuatanta, Stephen C. Woods, Heinz W. Harbach, Megan M. Wenner, Nina S. Stachenfeld, Timothy M. Griffin, Romain Meeusen, Kevin Pauw, Axel Urhausen, Li Li Ji, David C. Poole, Steven W. Copp, Daniel M. Hirai, Timothy I. Musch   +15 more
openaire   +3 more sources

Serum levels of osteoprotegerin and osteoprotegerin polymorphisms in Gaucher disease

British Journal of Haematology, 2006
SummaryBone involvement in Gaucher disease causes disability and reduced quality of life; loss of function and pain are important indications for enzyme replacement therapy. The purpose of this study was to ascertain whether osteoprotegerin (OPG), which decreases osteoclast activity, is indicative of incipient bone involvement by comparing OPG serum ...
Itai, Magal, Ehud, Lebel, Gheona, Altarescu, Menachem, Itzchaki, Bernard, Rudensky, A Joseph, Foldes, Ari, Zimran, Deborah, Elstein   +7 more
openaire   +2 more sources

Osteoprotegerin and Diabetic Macroangiopathy

Hormone and Metabolic Research, 2005
Osteoprotegerin (OPG) is a bone-related protein that is also present in the vasculature. Recent data suggest that it may play a special role in arterial disease among patients with diabetes. Diabetic macroangiopathy is characterized by a series of diffuse, non-atherosclerotic alterations that hypothetically increase the vulnerability of the vessel wall
L M, Rasmussen, T, Ledet
openaire   +2 more sources

Osteoprotegerin and kidney disease

Journal of Nephrology, 2014
Vascular calcification in chronic kidney disease (CKD) patients is associated to increased mortality. Osteoprotegerin (OPG) is a soluble tumor necrosis factor (TNF) superfamily receptor that inhibits the actions of the cytokines receptor activator of nuclear factor kappa-B ligand (RANKL) and TNF-related apoptosis-inducing ligand (TRAIL) by preventing ...
Alejandra, Montañez-Barragán, Isaias, Gómez-Barrera, Maria D, Sanchez-Niño, Alvaro C, Ucero, Liliana, González-Espinoza, Alberto, Ortiz   +5 more
openaire   +2 more sources

Osteoprotegerin as a marker of atherosclerosis: A systematic update

Scandinavian Cardiovascular Journal, 2012
Osteoprotegerin (OPG) may be involved in development of atherosclerosis. To evaluate plasma concentrations of OPG in individuals with stable coronary artery disease (CAD), acute coronary syndrome (ACS), peripheral artery disease (PAD), and cerebrovascular disease (CBVD) a systematic literature review was performed.Studies investigating OPG ...
Hosbond, Susanne Elisabeth, Poulsen, Tina Svenstrup, Diederichsen, Axel Cosmus Pyndt; id_orcid 0000-0002-1285-4826, Nybo, Mads, Rasmussen, Lars Melholt, Mickley, Hans   +5 more
openaire   +2 more sources

Role for osteoprotegerin in rheumatoid inflammation

Joint Bone Spine, 2004
Osteoprotegerin (OPG), a member of the TNF-receptor family expressed by osteoblasts, has documented effects on the regulation of bone metabolism. OPG inhibits bone resorption and binds with strong affinity to its ligand RANKL, thereby preventing RANKL from binding to its receptor RANK. This system is regulated by calcium-modifying hormones.
Nathalie, Saidenberg-Kermanac'h, Martine, Cohen-Solal, Natacha, Bessis, Marie-Christine, De Vernejoul, Marie-Christophe, Boissier   +4 more
openaire   +2 more sources

Osteoprotegerin and Diabetes-Associated Pathologies

Current Molecular Medicine, 2011
Osteoprotegerin (OPG) is a member of the tumour necrosis factor receptor superfamily of cytokines which, in spite of being initially described as a strong anti-resorptive factor, has lately been considered as a possible link between bone and vascular disease.
A M, Blázquez-Medela, J M, López-Novoa, C, Martínez-Salgado   +2 more
openaire   +2 more sources

Osteoprotegerin

2003
Bone loss is associated with several diseases, most notably rheumatoid arthritis (RA). Focal bone erosions appear to be a very early feature of RA and are associated with disease severity and long-term functional impairment, making targeted therapy for focal bone erosion an important goal of treatment.
Pettit, A. R., Gravellese, E. M.
openaire   +2 more sources

Osteoprotegerin in Cardiovascular Disease: Ally or Enemy?

Current Pharmaceutical Design, 2014
The OPG/RANK/RANKL axis is now recognized as a master regulator of bone remodeling, controlling osteoclast's maturation and extracellular matrix calcification. Nevertheless, a number of clinical and basic science studies conducted in the last few years demonstrated that the triad could be also involved in several physiological and pathological ...
Buso G, FAGGIN, ELISABETTA, PAULETTO, PAOLO, RATTAZZI, MARCELLO   +3 more
openaire   +3 more sources

Osteoprotegerin as a potential therapy for osteoporosis

Current Osteoporosis Reports, 2005
The discovery and characterization of the RANKL/RANK/OPG signaling pathway and the identification of its role in the pathogenesis of bone loss have provided the rationale for the development of drugs with the ability to modulate RANK-induced osteoclastogenesis.
openaire   +3 more sources